Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:liquid_biopsy_test
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
in vitro diagnostic
|
| gptkbp:companionDiagnosticFor |
LUMAKRAS (sotorasib)
TAGRISSO (osimertinib) |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:detects |
genetic alterations in ctDNA
|
| gptkbp:developedBy |
gptkb:Guardant_Health
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
solid tumors |
| gptkbp:numberOfGenes |
55
|
| gptkbp:regulates |
FDA-approved
|
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:type |
blood
|
| gptkbp:usedFor |
cancer genomic profiling
companion diagnostic |
| gptkbp:website |
https://www.guardanthealth.com/guardant360-cdx/
|
| gptkbp:bfsParent |
gptkb:Guardant360
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Guardant360 CDx
|